Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.43
- Piotroski Score 1.00
- Grade Neutral
- Symbol (ALIM)
- Company Alimera Sciences, Inc.
- Price $5.54
- Changes Percentage (-0.18%)
- Change -$0.01
- Day Low $5.53
- Day High $5.56
- Year High $5.65
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/24/2024
- Fiscal Year End N/A
- Average Stock Price Target $5.75
- High Stock Price Target $6.00
- Low Stock Price Target $5.50
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.25
- Trailing P/E Ratio -12.04
- Forward P/E Ratio -12.04
- P/E Growth -12.04
- Net Income $-20,132,000
Income Statement
Quarterly
Annual
Latest News of ALIM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
FDA grants breakthrough status to J&J's nipocalimab for SjD treatment
The FDA awarded Johnson & Johnson's nipocalimab its second breakthrough therapy designation for treating moderate-to-severe Sjögren's disease. The Phase II DAHLIAS study showed positive outcomes, lea...
By Yahoo! Finance | 1 week ago -
Detroit Lions agree to four-year, $97 million extension with defensive tackle Alim McNeill
Detroit Lions secure their young talent with Alim McNeill signing a four-year extension worth up to $97 million. The 315-pound defensive tackle has been a standout player, continuing the team's trend ...
By USA Today | 1 month ago -
The best fashion statement you can make this season? Buy pre-loved | Halima Begum
The author's father, a garment-maker, taught the value of clothing and reducing waste. They advocate for secondhand clothing to combat fast fashion's environmental impact and promote sustainability. J...
By The Guardian | 1 month ago
